Examining Changes in [18 F]FDG and [18 F]FLT Uptake in U87-MG Glioma Xenografts as Early Response Biomarkers to Treatment with the Dual mTOR1/2 Inhibitor AZD8055

Glucose Metabolism Measured by [18F]Fluorodeoxyglucose Positron Emission Tomography Is Independent of PTEN/AKT Status in Human Colon Carcinoma Cells

(2014) Quang-Dé Nguyen et al.   Translational Oncology

2-Deoxy-2-[18F]fluoro-d-glucose Positron Emission Tomography Demonstrates Target Inhibition with the Potential to Predict Anti-Tumour Activity Following Treatment with the AKT Inhibitor AZD5363

(2013) Juliana Maynard et al.   MOLECULAR IMAGING AND BIOLOGY

Limits of [18F]-FLT PET as a Biomarker of Proliferation in Oncology

(2013) Eliot T. McKinley et al.   PLoS One

Qualification of imaging biomarkers for oncology drug development

(2012) John C. Waterton et al.   EUROPEAN JOURNAL OF CANCER

Correlation between Ki-67 immunohistochemistry and 18F-Fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis

(2012) A. Chalkidou et al.   EUROPEAN JOURNAL OF CANCER

Longitudinal Imaging Studies of Tumor Microenvironment in Mice Treated with the mTOR Inhibitor Rapamycin

(2012) Keita Saito et al.   PLoS One

Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolismin vivo

(2011) Greg C. Smith et al.   BIOCHEMICAL JOURNAL

Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055: Figure 1

(2011) Gayle Marshall et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

3′-deoxy-3′-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma

(2011) Matthias R. Benz et al.   CANCER

[18F]FLT: An imaging biomarker of tumour proliferation for assessment of tumour response to treatment

(2011) Dmitry Soloviev et al.   EUROPEAN JOURNAL OF CANCER

Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis

(2011) Patsuree Cheebsumon et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

An Evaluation of 2-deoxy-2-[18F]Fluoro-D-Glucose and 3′-deoxy-3′-[18F]-Fluorothymidine Uptake in Human Tumor Xenograft Models

(2011) Heather Keen et al.   MOLECULAR IMAGING AND BIOLOGY

18F-FLT PET as a Surrogate Marker of Drug Efficacy During mTOR Inhibition by Everolimus in a Preclinical Cisplatin-Resistant Ovarian Tumor Model

(2010) N. Aide et al.   JOURNAL OF NUCLEAR MEDICINE

18F-FLT PET/CT for Early Response Monitoring and Dose Escalation in Oropharyngeal Tumors

(2010) E. G. C. Troost et al.   JOURNAL OF NUCLEAR MEDICINE

MRI with Magnetic Nanoparticles Monitors Downstream Anti-Angiogenic Effects of mTOR Inhibition

(2010) Alexander R. Guimaraes et al.   MOLECULAR IMAGING AND BIOLOGY

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo

(2009) D Cejka et al.   BRITISH JOURNAL OF CANCER

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

(2009) C. M. Chresta et al.   CANCER RESEARCH

Early Response Assessment in Gastrointestinal Stromal Tumors With FDG PET Scan 24 Hours After a Single Dose of Imatinib

(2009) Ajit Shinto et al.   CLINICAL NUCLEAR MEDICINE

[18F]Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy

(2009) Wen Wee Ma et al.   JOURNAL OF CLINICAL ONCOLOGY

Performance Evaluation of the Inveon Dedicated PET Preclinical Tomograph Based on the NEMA NU-4 Standards

(2009) Q. Bao et al.   JOURNAL OF NUCLEAR MEDICINE

mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)

(2008) Juan M. García-Martínez et al.   BIOCHEMICAL JOURNAL

Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging

(2008) C. R. Schnell et al.   CANCER RESEARCH

Changes in Tumor Metabolism as Readout for Mammalian Target of Rapamycin Kinase Inhibition by Rapamycin in Glioblastoma

(2008) L. H. Wei et al.   CLINICAL CANCER RESEARCH

Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma

(2008) Tim F Cloughesy et al.   PLOS MEDICINE